Propranolol

Inderal

Propranolol (Inderal) is a cognitive & mood research compound. Non-selective beta blocker that crosses the blood-brain barrier. Blunts the peripheral adrenaline response — tremor, tachycardia, sweating — which is why it works for performance anxiety without sedating.

How Propranolol works

Non-selective beta blocker that crosses the blood-brain barrier. Blunts the peripheral adrenaline response — tremor, tachycardia, sweating — which is why it works for performance anxiety without sedating.

Proposed benefits

Researched for focus, memory, neuroprotection, mood and stress resilience.

Where to get Propranolol

The evidence for Propranolol

Graded by what exists behind each claim.

✅ Clinically validated

• Approved for decades with enormous trial data across hypertension, angina, arrhythmia, migraine prophylaxis and essential tremor. Also well-evidenced for performance anxiety, where trials show reduced physical symptoms without sedation.
• Trials in memory reconsolidation — giving it while a traumatic memory is recalled — have produced genuinely interesting results in PTSD research, though not a licensed indication.

📊 Correlative data

• Very wide clinical use. The consistently reported limitation is that it blunts the physical side of anxiety and not the cognitive side — the racing heart goes, the worry does not.

🧪 Theoretical / extrapolated

• A non-selective beta-blocker: it blocks β1 receptors in the heart and β2 in the lungs and vasculature, and unlike most beta-blockers it is lipophilic enough to cross into the brain.
• Both of those properties matter. β2 blockade is why it is contraindicated in asthma, and CNS penetration is why it works on performance anxiety and memory reconsolidation where cardioselective beta-blockers do not.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Propranolol actually does

Propranolol is a competitive antagonist at both beta-adrenergic receptors, with no intrinsic sympathomimetic activity. The label is explicit that it is nonselective and that it “competes with beta-adrenergic receptor-stimulating agents for available receptor sites”, with membrane-stabilizing (quinidine-like) effects on the cardiac action potential appearing only at higher doses U.S. Food and Drug Administration 2024. Three separate properties are doing three separate jobs, and most writing about this drug collapses them into one.

Beta-1 blockade is the cardiac half. Fewer beta-1 receptors available to adrenaline and noradrenaline means a lower heart rate, reduced contractility and reduced myocardial oxygen demand — which is why the label lists angina as an indication and describes the mechanism there as blocking catecholamine-induced increases in rate and contractility U.S. Food and Drug Administration 2024.

Beta-2 blockade is the half that gets people into trouble and the half that stops the tremor. Beta-2 receptors sit on bronchial smooth muscle, on vascular smooth muscle and — the part almost nobody names — on skeletal muscle spindles, where circulating adrenaline amplifies physiological tremor. Blocking beta-2 is therefore simultaneously the reason propranolol steadies a hand and the reason the label lists bronchial asthma as an outright contraindication. You cannot buy one without the other from a nonselective agent; that is what nonselective means.

Lipophilicity is the third property and it is structural. Witczynska 2025 is a crystallographic review of exactly this: propranolol's naphthalene ring system gives it high lipophilicity and central nervous system penetration, and the paper works through high-resolution structures of the human beta-2 adrenergic receptor — notably PDB 6PS5, obtained by serial femtosecond crystallography — to identify the binding determinants behind its affinity and antagonism. It also reports the structural comparison quantitatively, with superimposition RMSD values of 0.032 against alprenolol, 0.078 against carvedilol and 1.078 against timolol. A naphthalene instead of a benzene is the difference between a beta-blocker that reaches the brain and one that does not, and it is the entire basis for using this drug rather than atenolol when the target is a psychological state.

And it is a racemate whose halves are not equal. Witczynska 2025 reports that the S-enantiomer has greater receptor affinity and pharmacological potency than the R-form. Commercial propranolol is the racemate, so half of every tablet is the weaker enantiomer — which still contributes to the membrane-stabilizing and central effects that are not receptor-mediated. The same review notes off-target interactions with non-canonical proteins including lactoferrin, which is a reminder that ‘beta-blocker’ describes the intended target and not the full binding profile.

Cell, rodent, human — and where it stops

Step one, the approved indications, which are cardiovascular and neurological. The label covers hypertension, angina pectoris, migraine prophylaxis and improvement of NYHA functional class in symptomatic hypertrophic subaortic stenosis U.S. Food and Drug Administration 2024. The dosing is substantial: 80 mg once daily initially for hypertension with a usual maintenance of 120–160 mg daily and a maximum of 640 mg; angina averaging about 160 mg daily; migraine prophylaxis at 160–240 mg daily, reassessed if there is no response within 4–6 weeks at the maximal dose.

Step two, the use this site's readers actually have, and it rests on a small 1982 study that is better than its size suggests. Brantigan 1982 studied stage fright in professional musicians — 29 subjects across two trials, propranolol double-blind, with the beta-agonist terbutaline as an active comparator in the opposite direction. Symptoms were scored by questionnaire and by the State-Trait Anxiety Inventory, and the quality of the musical performance was rated by experienced music critics who did not know the treatment. Beta blockade eliminated the physical impediments to performance, eliminated the dry mouth, and significantly improved the rated quality of the performance — without tranquilization. Beta stimulation made stage fright worse. That is a two-directional result with a blinded external endpoint, which is a stronger design than most modern anxiety trials.

Step three, the modeling work that shows where the dose stops being safe to assume. Kalam 2021 built a whole-body physiologically based pharmacokinetic model of propranolol in healthy and cirrhotic populations, validated it against observed data with all predicted parameters within a 2-fold range of observed, and found a significant increase in plasma concentration and a decrease in drug clearance in progressive stages of liver cirrhosis. Propranolol is cleared by the liver; a damaged liver produces a different drug exposure from the same tablet.

The obstacles, stated exactly. (1) Situational anxiety is not on the label U.S. Food and Drug Administration 2024. The 1982 musician study is real and blinded and it enrolled 29 people; there is no large randomized trial of propranolol for performance anxiety with a modern design. (2) The dose gap is enormous and nobody has bridged it: the label's indications run at 80–640 mg daily, and the situational use on this site's card is 10–40 mg as needed. A 10 mg dose is an eighth of the smallest labeled daily dose, and no dose-response study exists for the anxiety endpoint. (3) The effect is on the peripheral limb of anxiety. The consistently reported limitation, and the card says so too, is that the racing heart goes and the worry does not. (4) Every number in the PBPK work and the label describes chronic dosing to steady state; a single tablet taken an hour before a presentation is a different pharmacological situation and has never been characterized in its own right.

Propranolol pharmacokinetics — how much of it actually gets in

Route: oral, and the first-pass effect is the dominant fact. Propranolol is highly lipophilic and almost completely absorbed, and then the liver takes most of it: the label states it undergoes “high first pass metabolism” and that only about 25% of propranolol reaches the systemic circulation U.S. Food and Drug Administration 2024. Three-quarters of every tablet is destroyed before it reaches a receptor, which is why the oral doses look large next to the intravenous ones and why anything that changes hepatic blood flow or hepatic enzyme activity changes the exposure disproportionately.

What degrades it, with the split. The label gives the metabolic routes as aromatic hydroxylation 42%, N-dealkylation with side-chain oxidation 41%, and glucuronidation 17%, carried by CYP2D6, CYP1A2 and CYP2C19, and names 4-hydroxypropranolol as an active metabolite that is itself a weak CYP2D6 inhibitor U.S. Food and Drug Administration 2024. Two of those three enzymes are polymorphic or inducible: CYP2D6 has poor-metabolizer genotypes, and CYP1A2 is induced by tobacco smoke and inhibited by fluvoxamine. So the same tablet produces materially different exposures in different people for reasons that are knowable in advance and almost never checked.

Half-life, and which number belongs to which product. The label read here is for the long-acting capsule: peak blood levels occur about 6 hours after administration and the apparent plasma half-life is about 10 hours, with the long-acting form producing AUCs of approximately 60% to 65% of comparable divided daily doses of the immediate-release tablet, because more of the slowly-released drug meets the liver on the way through U.S. Food and Drug Administration 2024. This site's card lists about 4 hours, which is the immediate-release figure — and immediate-release is the right product for the as-needed use the card describes. Both numbers are correct about different things, and mixing them is how somebody ends up taking a long-acting capsule an hour before a presentation and concluding the drug does nothing.

Protein binding, which matters more here than usual. About 90% is bound to plasma proteins — albumin and alpha-1-acid glycoprotein — and the label notes the binding is stereoselective U.S. Food and Drug Administration 2024. Alpha-1-acid glycoprotein is an acute-phase protein: it rises in inflammation, infection, trauma and after surgery. When it rises, more propranolol is bound and less is free, so the same dose is pharmacologically weaker during an illness — and the stereoselectivity means the free fraction is not even the same enantiomeric mixture as the tablet.

And the liver again. Kalam 2021 quantified what everyone assumes: clearance falls and plasma concentration rises with progressive cirrhosis. For a drug where 75% of an oral dose is normally removed on first pass, a failing liver does not reduce exposure by a little — it removes the mechanism that was limiting exposure in the first place.

What would have to be true, and how you would know it was not

Five predictions with a marker, a direction and a window. The first is the cheapest falsification test in this entire Vault and the fourth is the one that argues against taking it.

1. Resting heart rate should fall, and you need no laboratory to check it. Beta-1 blockade lowers rate; that is the mechanism, and it is the label's own account of how the drug treats angina U.S. Food and Drug Administration 2024. Measure resting heart rate seated, same time of day, for three days before and on the day of a dose, at 60 and 120 minutes post-dose. If a 10–40 mg immediate-release dose does not lower resting heart rate by anything measurable at 60–120 minutes, either the absorption or the product is wrong, and no subjective impression should override that.

2. The rise in heart rate under stress should be blunted more than the resting rate is. The effect is competitive antagonism, so it scales with how much catecholamine is competing: little at rest, a great deal on a stage. That is the mechanistic reading of Brantigan 1982, where the physical impediments went and the performance improved. The read-out is the difference between resting and peak heart rate on a performance day, and it should shrink far more than the resting number does.

3. Nothing on a standard blood panel should move, and saying so is the useful result. Propranolol has no predicted effect on a CBC, a CMP, a lipid panel or thyroid function at these doses, and the honest version of a bloodwork section here is that there is no marker to chase. A baseline Comprehensive Metabolic Panel (CMP) is reasonable for anything taken daily and long term, mainly because hepatic clearance governs the exposure Kalam 2021, and beyond that there is nothing specific.

4. The prediction that cuts against it: blunted heart rate is blunted training stimulus, and blunted hypoglycemia warning. Two separate costs, both mechanistic. Cardiovascular training adaptations are driven partly by the heart-rate and contractility response to exercise; suppressing that response with a nonselective antagonist should reduce the achievable training intensity, and anyone using heart rate to prescribe training zones will misread their own effort for as long as the drug is on board. Separately, the label states beta-blockers “may prevent early warning signs of hypoglycemia, such as tachycardia, and increase the risk for severe or prolonged hypoglycemia” U.S. Food and Drug Administration 2024 — which matters enormously to a reader stacking this with a GLP-1 agonist, insulin, or a hard fasted training session.

5. Stopping abruptly should produce a rebound, and the label puts a timescale on the taper. Chronic beta blockade upregulates beta receptors; withdrawing the antagonist leaves that expanded receptor population exposed to normal catecholamine tone. The label reports exacerbation of angina and myocardial infarction following abrupt discontinuance and directs that dosage be gradually reduced over at least a few weeks U.S. Food and Drug Administration 2024. Anyone who has been taking this daily rather than occasionally should treat a rising resting heart rate above their own pre-treatment baseline as the expected rebound signal.

What nobody has tested yet

Nobody has run a modern dose-response study for the situational anxiety use. Brantigan 1982 is 29 musicians in 1982. The 10–40 mg range in circulation has never been compared against itself — 10 versus 20 versus 40 mg, blinded, with heart rate, a validated anxiety scale and a blinded external performance rating. That study would cost very little, the drug is generic, and the result would immediately tell hundreds of thousands of people whether they are taking three times more than they need.

Nobody has genotyped CYP2D6 against the anxiety response. CYP2D6 carries 42% of propranolol's metabolism via aromatic hydroxylation U.S. Food and Drug Administration 2024 and is one of the most-studied polymorphic enzymes in medicine. Whether poor metabolizers need a lower dose for the same tremor suppression, or get more central effect at the same dose, has not been published — despite the genotype test being cheap and the endpoint being measurable with a pulse oximeter.

Nobody has measured whether beta blockade before resistance training blunts the adaptation. The mechanistic case is real: catecholamines drive part of the acute exercise response, and this drug antagonizes both receptors it acts through. A trial with two groups training identically for eight weeks, one on 20 mg pre-session and one on placebo, with lean mass and one-rep max as endpoints, has not been run. Given how many people take this before public speaking and then go to the gym, the absence is odd.

Nobody has characterized the single-dose situational pharmacokinetics. Everything published describes chronic dosing to steady state U.S. Food and Drug Administration 2024 Kalam 2021. The question a reader actually has — take it how long before the event, and for how many hours does the heart-rate effect last after a single 20 mg immediate-release tablet — is answerable with a Holter monitor and twenty volunteers, and has no published answer.

Propranolol — its own safety story, not its class's

This drug has real contraindications, and they are absolute rather than cautionary. The label lists four: cardiogenic shock; sinus bradycardia and greater than first-degree atrioventricular block; bronchial asthma; and known hypersensitivity to propranolol hydrochloride U.S. Food and Drug Administration 2024. Asthma is the one this site's readership hits: beta-2 blockade removes the bronchodilator response to endogenous and administered catecholamines, so the label's warning is that propranolol “may provoke a bronchial asthmatic attack” and that the same blockade also blunts the rescue inhaler. That combination — provoke the attack, disable the treatment — is why it is a contraindication rather than a warning.

The stacking error this site's card already flags, with the receptor logic behind it. Clenbuterol and high-dose stimulants are beta-agonists. Giving a nonselective beta-antagonist alongside them does not simply cancel them out: catecholamines also act at alpha-adrenergic receptors, which propranolol does not touch, so blocking beta-2-mediated vasodilation while alpha-1-mediated vasoconstriction runs unopposed can raise blood pressure sharply. Brantigan 1982 is the mirror image of this in the useful direction — it gave a beta-agonist deliberately and found stage fright got worse.

Abrupt cessation is the label's own warning and it has killed. The label reports exacerbation of angina and myocardial infarction following abrupt discontinuance and instructs that the dose be reduced gradually over at least a few weeks U.S. Food and Drug Administration 2024. This applies to anyone taking it regularly, not only to cardiac patients, because the receptor upregulation that causes the rebound is a property of chronic blockade rather than of the underlying disease.

Two masking effects that matter to this audience specifically. First, hypoglycemia: the label warns that beta-blockers may prevent early warning signs such as tachycardia and increase the risk for severe or prolonged hypoglycemia U.S. Food and Drug Administration 2024 — directly relevant to anyone running a GLP-1 agonist, insulin, or long fasted sessions. Second, thyroid: beta blockade may mask certain clinical signs of hyperthyroidism, and abrupt withdrawal in a thyrotoxic patient may precipitate a thyroid storm. Both are cases where the drug removes the signal rather than the problem.

The rest of the label's adverse-reaction list, without invented rates. The label reports these without percentages, and it is worth being honest that no incidence figure exists to quote: bradycardia, congestive heart failure, hypotension, intensification of AV block and Raynaud's phenomenon; light-headedness, mental depression, insomnia, fatigue, visual disturbance and hallucinations; bronchospasm; nausea, vomiting, diarrhea and constipation; Stevens-Johnson syndrome and toxic epidermal necrolysis; anaphylactoid reactions; agranulocytosis and thrombocytopenic purpura; male impotence and alopecia U.S. Food and Drug Administration 2024. Two of those deserve naming for this readership: mental depression and fatigue, because a lipophilic beta-blocker reaches the brain by design Witczynska 2025 and the same property that makes it work on performance anxiety is what puts central adverse effects on the list; and male impotence, on a site where most other pages are about improving exactly that.

Sources read for this page

• U.S. Food and Drug Administration. INDERAL LA (propranolol hydrochloride) extended-release capsules - full prescribing information (NDA 018553).. FDA approved labeling, revision 2024
• Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright.. Am J Med 1982 · PMID 6120650
• Witczynska A, Fijalkowski L, Mirowska-Guzel D, Blecharz-Klin K, Nowaczyk A. Structural and Pharmacological Insights into Propranolol: An Integrated Crystallographic Perspective.. Int J Mol Sci 2025 · PMID 41155370
• Kalam MN, Rasool MF, Alqahtani F, Imran I, Rehman AU, Ahmed N. Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.. Drug Des Devel Ther 2021 · PMID 33762817

Propranolol — safety, predicted from mechanism

Propranolol — interference & stacking

Bloodwork to run alongside Propranolol

Baseline first, then again at 8–12 weeks.

The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.

Check results you already have → · All 103 markers A–Z

Propranolol — frequently asked questions

What Propranolol is used for

Propranolol appears under 1 goal in the goal router.

Related Cognitive & Mood compounds

← Explore the full Protocol Vault

↑ Back to on this page